The major depressive disorder (MDD) therapy market is crowded and highly genericized. The prominent use of drugs such as selective serotonin reuptake inhibitors (SSRIs) as early-line treatments…
Approximately 80% of rare diseases have a genetic etiology. Gene therapies have the potential to transform the treatment of rare diseases and, in some cases, provide a functional cure. However,…
The treatment of breast cancer is associated with strong commercial opportunity because of the disease’s high incidence, long treatment durations, and multiple lines of therapy. The CDK4/6…
The treatment of opioid-induced constipation (OIC) relies on various prescription medications, including several agents approved for irritable bowel syndrome with constipation (IBS-C) or chronic…
Systemic lupus erythematosus (SLE) is a complex autoimmune disease that can affect nearly any organ or system in the body. As a result, its course, manifestations, and treatment approach can be…
Although tumor necrosis factor-alpha (TNF-α) inhibitors remain the most widely prescribed biologics for rheumatoid arthritis (RA) patients refractory to conventional DMARD treatment (the first-…
The rising rates of antimicrobial resistance (AMR) have created an emergent need for development and discovery of antibiotics with activity against drug-resistant gram-negative pathogens (GNPs)…
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Historically, it has had a relatively poor prognosis, including low five-year overall survival rates. Chemotherapy…
The severe to very severe chronic obstructive pulmonary disease (COPD) drug market is becoming increasingly crowded as several LAMAs, LABA/ICSs, LABA/LAMAs, and, most recently, LABA/LAMA/ICSs…
The availability of multiple targeted therapies with diverse mechanisms of action, including biologics / biosimilars and oral agents, along with conventional treatments, makes the rheumatoid…
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Historically, the prognosis has been poor. Chemotherapy backbones have long dominated treatment, but there is an ongoing…
We expect the ulcerative colitis (UC) therapy market to grow steadily over the next decade, primarily driven by the increasing use of non-tumor necrosis factor (TNF) biologics (e.g., Takeda’s…
The Crohn’s disease (CD) therapy market is expected to see increasing use of biologics / targeted oral therapies and grow steadily over the next 10 years. The well-established TNF-α inhibitors (…
Clarivate Epidemiology’s coverage of overactive bladder (OAB) comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We report…